FBRX News and Press, Forte Biosciences Inc. From 11/14/22

-Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Boa...

-FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications - -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors- -Ended third quarter 2022 with approximately $44.0 ...

Funicular Funds, which owns 8% of the outstanding shares of Forte Biosciences ( NASDAQ: FBRX ), excoriated the company's board of directors in a letter over a recent capital raise. In an SEC filing , Funicular said the letter addressed the "Board’s failure ...

Fears the Board has Diluted Shareholders for Self-Serving Purposes Following the Emergence of Four 13D Filers, Suggesting the Directors Have Potentially Breached Their Fiduciary Duties Notes the Company Trades at a ~40% Discount to Cash Urges the Board to Rev...

FB-401, the lead asset failed in clinical trials. The company has one very early-stage asset they intend to move forward in the clinic, FB-102. Investors are likely to encounter dilution, a high degree of clinical risk and there is insufficient evidence to assess whether FB-401 ha...

Forte Biosciences press release ( NASDAQ: FBRX ): GAAP EPS of -$0.21. Ended second quarter 2022 with approximately $38.5 million in cash and cash equivalents For further details see: Forte Biosciences GAAP EPS of -$0.21

-Forte Biosciences is Developing a Novel Pipeline for the Treatment of Autoimmune Diseases- -Leadership Strengthened with Appointments of Hubert Chen, M.D. as Chief Scientific Officer and Stephen Doberstein, Ph.D. to the Board of Directors- -Ended second quarter 2022 w...

Pineapple Energy ( PEGY ) +75% . Atlas ( ATCO ) +24% after receives takeover offer from Poseidon. Pagaya Technologies  ( PGY ) +22% . The Joint ( JYNT ) +22% GAAP EPS of $0.02 beats by $0.01, revenue of $25.06M beats by $1.51M. ...

A pair of large shareholders of Forte Biosciences ( NASDAQ: FBRX ) are making demands that could impact the company's future, including the suggestion that the company liquidate. In a Wednesday SEC filing , Brad Leonard, managing member of BML Capital Management, which...

Forte Biosciences (NASDAQ:FBRX) appoints Dr. Hubert Chen, MD as the Chief Scientific Officer and President. Prior to joining the company, Dr. Chen was the Chief Medical Officer of Metacrine. “Dr. Chen is a very accomplished drug development scientist and physician and we...